Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pembrolizumab plus olaparib maintenance versus pembrolizumab plus pemetrexed maintenance in first-line metastatic nonsquamous NSCLC
2018-004720-11Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab, olaparib, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Apr 2019; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-004720-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004720-11.